Biophysical identification of natural human antibody targets

Abstract

A natural human antibody, PAT-SM6, isolated using technology developed by the partner organisation (Patrys), offers promise as a therapy to reduce mortalities due to cancer, the leading cause of death in Australia. The novelty of the approach pioneered by Patrys is the direct production of human antibodies which avoids undesirable side effects associated with the use of antibodies containing non-human components. This project is to discover the specificity of PAT-SM6 for proteins and protein complexes and how these interactions lead to tumour cell death. This work will enhance the effectiveness of human antibody therapies and help in the development of this fast growing area within the biote..

Related publications (2)

Simultaneous Binding of the Anti-Cancer IgM Monoclonal Antibody PAT-SM6 to Low Density Lipoproteins and GRP78

Zachary Rosenes, Yee-Foong Mok, Shuo Yang, Michael DW Griffin, Terrence D Mulhern, Danny M Hatters, Frank Hensel, Geoffrey J Howlett

2013-04-19

The Anti-Cancer IgM Monoclonal Antibody PAT-SM6 Binds with High Avidity to the Unfolded Protein Response Regulator GRP78

Zachary Rosenes, Terrence D Mulhern, Danny M Hatters, Leodevico L Ilag, Barbara E Power, Chris Hosking, Frank Hensel, Geoffrey J Howlett, Yee-Foong Mok

2012-09-19